Christopher Richards

Christopher Richards is a Professor in the Department of Chemistry at University of Kentucky, with significant affiliations including the Markey Cancer Center/Cancer Research Priority Initiative, Neuroscience Research Priority Area, Substance Use Priority Research Area, and Translational Oncology Research Program. His research spans multiple disciplines with a focus on receptor neuroscience, particularly nicotinic acetylcholine receptors, and the application of single-molecule imaging techniques to understand cellular processes.

Dr. Richards earned his Doctor of Philosophy from Georgia Institute of Technology in 2009. His research profile shows significant expertise in:

• Receptor Neuroscience (100%)
• Nicotinic Acetylcholine Receptor Neuroscience (70%)
• Nicotinic Receptor Neuroscience (67%)
• Cell Membrane Neuroscience (64%)
• Endoplasmic Reticulum Neuroscience (63%)
• Stoichiometry Biochemistry, Genetics and Molecular Biology (48%)
• Macrophage Medicine and Dentistry (46%)
• Single Molecule Imaging Biochemistry, Genetics and Molecular Biology (37%)

His research program is highly active with 66 publications and 54 projects and grants, including significant funding from the National Institute on Aging, National Institute of Allergy and Infectious Diseases, and Craig H. Neilsen Foundation. Recent work focuses on macrophage-engineered vesicles for cancer treatment, blood-brain barrier research related to nicotine withdrawal, and single-molecule analysis of receptor assembly in neural and cardiac tissues.

His publications since 2023 reveal strong trends toward vesicle-based cancer therapeutics, particularly for ovarian cancer, and sophisticated single-molecule techniques to study receptor assembly and function. The research demonstrates significant interdisciplinary collaboration across neuroscience, cancer biology, and infectious disease fields.

Dr. Richards has received research recognition including a notable award in 2023. His work contributes to UN Sustainable Development Goals, particularly in areas related to health and well-being.

His research group maintains active collaborations across multiple departments, with current projects including "Blood-Brain Barrier Dysfunction in Alzheimer's Disease," "Understanding the Mechanism of SARS-CoV-2 Entry by Single-Molecule Approaches," and "Engineered Nanovesicles For Macrophage Reprogramming In Spinal Cord Injury." These projects demonstrate both fundamental scientific inquiry and translational applications.